Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Regado Biosciences nets $43.4mm through its IPO

Executive Summary

Regado Biosciences Inc. (anti-thrombotic drug systems) netted $43.4mm through the initial public offering of 11.67mm common shares (including the overallotment) at $4. Shortly after filing the company announced plans to sell 5mm shares at $14-16 each, but just weeks before pricing, the company said it would sell 8.4mm shares at $5. Existing shareholders bought 7.9mm of the IPO shares.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies